Page last updated: 2024-12-07

22-hydroxycholesterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

22-hydroxycholesterol is a cholesterol derivative synthesized in the liver and other tissues. It has been shown to have both beneficial and detrimental effects on human health. Its synthesis involves the hydroxylation of cholesterol at the 22-position by the enzyme CYP46A1. 22-hydroxycholesterol acts as a ligand for the nuclear receptor LXR, promoting the expression of genes involved in cholesterol efflux and reducing cholesterol levels in the body. It has also been linked to the regulation of immune responses, inflammation, and neuroprotection. However, high levels of 22-hydroxycholesterol have been associated with increased risk of cardiovascular disease and neurodegenerative disorders. Therefore, understanding the precise role of 22-hydroxycholesterol in various physiological and pathological processes is crucial for developing potential therapeutic strategies.'

Cross-References

ID SourceID
PubMed CID107724
CHEMBL ID3218924
CHEBI ID166802
SCHEMBL ID103514
MeSH IDM0044614

Synonyms (18)

Synonym
CHEBI:166802
(3s,8s,9s,10r,13s,14s,17r)-17-[(2s)-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
17711-16-9
cholest-5-ene-3beta,22-diol
cholest-5-en-3beta,22-diol
LMST01010054
22-hydroxycholesterol
tj9hv8vpd2 ,
cholest-5-ene-3,22-diol, (3beta)-
unii-tj9hv8vpd2
CHEMBL3218924
SCHEMBL103514
DTXSID30904340
Q4631298
PD015597
(1r,3as,3bs,7s,9ar,9bs,11as)-1-[(2s)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-ol
(3.beta.)-cholest-5-ene-3,22-diol
cholest-5-ene-3.beta.,22-diol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These data suggest that 22R-hydroxycholesterol binds to Abeta and the formed 22R-hydroxycholesterol/Abeta complex is not toxic to rodent and human neurons."( 22R-Hydroxycholesterol protects neuronal cells from beta-amyloid-induced cytotoxicity by binding to beta-amyloid peptide.
Brown, RC; Greeson, J; Papadopoulos, V; Teper, G; Yao, ZX, 2002
)
0.31
" We now demonstrate that this osteogenic combination of oxysterols prevents the adverse effects of oxidative stress on differentiation of M2 cells into mature osteoblastic cells."( Osteogenic oxysterols inhibit the adverse effects of oxidative stress on osteogenic differentiation of marrow stromal cells.
Amantea, CM; Hahn, TJ; Kha, HT; Parhami, F; Richardson, JA; Shouhed, D, 2005
)
0.33
"While glucocorticoids (GC) exert beneficial effects (anti-inflammatory), they also have adverse effects on the epidermis including decreased epidermal differentiation, decreased keratinocyte proliferation, and decreased cutaneous permeability barrier homeostasis."( Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis.
Chang, S; Choi, EH; Demerjian, M; Elias, PM; Feingold, KR; Man, MQ, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Results showed that 22SHC was well absorbed after oral administration and distributed to most organs and mainly excreted in feces."( Dietary supplementation with 22-S-hydroxycholesterol to rats reduces body weight gain and the accumulation of liver triacylglycerol.
Fjeldheim, AK; Jensen, J; Nikolić, N; Pettersen Hessvik, N; Rustan, AC; Thoresen, GH; Tranheim Kase, E, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" The hCG dose-response curve was shifted to the right by the addition of IL-2."( Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis.
Calkins, JH; Guo, H; Lin, T; Sigel, MM, 1990
)
0.28
"Rat testicular interstitial fluid and hydroxycholesterol both stimulated testosterone production by isolated Leydig cells in vitro in a dose-dependent manner, but the dose-response lines were not parallel."( The interaction of hCG, hydroxysteroids and interstitial fluid on rat Leydig cell steroidogenesis in vitro.
de Kretser, DM; Jenkin, G; Risbridger, GP, 1986
)
0.27
" These data suggest that lead directly inhibited steroidogenesis by decreasing StAR protein expression and the activities of P450scc and 3beta-HSD enzymes with a dose-response trend in MA-10 cells."( The inhibitory effects of lead on steroidogenesis in MA-10 mouse Leydig tumor cells.
Huang, BM; Lai, HY; Liu, MY; Tsai, ML; Yang, BC; Yang, HY, 2001
)
0.31
" The present experiments focused on establishing a dose-response for such an effect and identifying the point(s)of impact of this compound along the steroidogenic pathway that underlie this suppression."( Alterations in ovarian follicular progesterone secretion by elevated exposures to the drinking water disinfection by-product dibromoacetic acid: examination of the potential site(s) of impact along the steroidogenic pathway.
Goldman, JM; Murr, AS, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cholanoid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID81186Evaluated for the percent suppression of elevated liver HMG-CoA reductase in Diazoesterol treated rats; No data1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
22-Hydroxycholesterol derivatives as HMG CoA reductase suppressors and serum cholesterol lowering agents.
AID184870Minimum effective dose necessary to produce >=25% decrease of elevated liver HMG CoA reductage levels1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
22-Hydroxycholesterol derivatives as HMG CoA reductase suppressors and serum cholesterol lowering agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (181)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (9.94)18.7374
1990's44 (24.31)18.2507
2000's75 (41.44)29.6817
2010's41 (22.65)24.3611
2020's3 (1.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.07 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index29.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other186 (98.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]